GLP-1 medicines are reshaping diabetes and weight-loss care, driving a race for customers, capital and market share. The SANOR GLP-1 Market Monitor tracks the companies, deals and commercial developments shaping this market.
Updated 23 September 2026
Annual global market size · 2025
Forecast annual growth (CAGR) · 2025–2035
Last 12 months
Last 12 months
Revvity agreed to acquire Human Cell Design, adding human-relevant cell models used in diabetes, obesity and GLP-1 drug discovery. Financial terms were not disclosed.
RevvityRose Pharma will use MannKind’s inhalation technology to develop an inhaled version of an experimental weight-loss drug. MannKind receives a stake in Rose Pharma and a share of potential future sales.
MannKindInvestors led by BVF Partners are providing Superluminal with $60 million to advance an experimental obesity treatment. Lilly is participating as an investor in this funding round.
Gan & Lee developed bofanglutide; Menarini will seek approval and sell the medicine in 39 European countries if approved. Menarini will pay Gan & Lee €62 million initially for the exclusive rights.
Genentech, part of Roche, will pay Hanmi $190 million initially for rights to develop and sell Hanmi’s experimental obesity medicine outside South Korea. Further payments depend on progress and sales.
Investors will provide Poolbeg with £3.5 million in exchange for new shares. Poolbeg says the money will help fund trials of a GLP-1 obesity treatment taken by mouth and a separate cancer-support medicine.
Poolbeg PharmaHims & Hers says it has bought Eucalyptus, adding an established digital healthcare business in several overseas markets. Payments for the acquisition can total up to $1.15 billion, subject to conditions and adjustments.
Hims & HersGrow revenue at each location and build a commercial model that can scale across a clinic group.
Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.
SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.
SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.
All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.
